Carvolix SA (EPA:CVX)
France · Delayed Price · Currency is EUR 6.32
+0.38 (6.40%)
Aug 6, 2026, 5:35 PM CET
Carvolix Revenue
In the year 2025, Carvolix had annual revenue of 900.00K EUR, down -90.49%. Carvolix had revenue of 323.00K in the half year ending December 31, 2025, a decrease of -92.97%.
Revenue
900.00K
Revenue Growth
-90.49%
P/S Ratio
391.01
Revenue / Employee
11.84K
Employees
68
Market Cap
351.91M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 900.00K | -8.57M | -90.49% |
| Dec 31, 2024 | 9.47M | 5.51M | 138.96% |
| Dec 31, 2023 | 3.96M | 2.62M | 195.91% |
| Dec 31, 2022 | 1.34M | -112.00K | -7.72% |
| Dec 31, 2021 | 1.45M | 627.00K | 76.09% |
| Dec 31, 2020 | 824.00K | -605.00K | -42.34% |
| Dec 31, 2019 | 1.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Guerbet | 798.67M |
| Eurobio Scientific Société anonyme | 168.60M |
| Biosynex | 95.19M |
| Diagnostic Medical Systems | 52.86M |
| Median Technologies | 23.47M |
| Novacyt | 22.96M |
| Implanet | 12.47M |
| Mauna Kea Technologies | 8.91M |